Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly’s stock is entering the new week as one of the most closely watched names on Wall Street. As of this weekend, LLY is trading near $1,060 per share, valuing the company at roughly $1 trillion, after becoming the first drugmaker ever to join the trillion‑dollar market‑cap club. Reuters

NYSE:LLY · Pharmaceutical Industry · Stock Market

Eli Lilly (LLY) Stock Today, November 22, 2025: Trillion‑Dollar Milestone, New Board Member and Fresh Access Deals Fuel Momentum

Eli Lilly heads into the weekend of November 22, 2025, sitting near record highs and fresh off becoming the first drugmaker ever to join the $1 trillion market‑cap club. A powerful combination of blockbuster obesity drugs, new access deals with the U.S. government and employers, and bullish analyst sentiment is keeping LLY at the center of Wall Street’s attention. Reuters+1
22 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

US Stock Market Today, November 22, 2025: Wall Street Ends a Wild Week Higher as Fed Cut Bets Rise and AI Rally Shows Cracks

After one of the rockiest stretches since spring, the US stock market heads into the weekend bruised but not broken. A powerful rally on Friday, November 21, 2025, pushed the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite solidly higher, even as all three benchmarks still finished the week in the red. AP News+1
22 November 2025
··

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

As of 00:40 UTC on Nov. 15, LLY is ~$1,025. The 52‑week range is roughly $624–$1,034, and third‑party dashboards peg market cap in the $920–$970B range, reflecting price swings and share count. On trailing metrics the stock trades near 50x earnings; on Lilly’s 2025 EPS guide midpoint, the forward P/E is ~44x. That premium embeds continued GLP‑1 scale‑up and pipeline options. Lightyear
15 November 2025
·
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals, Inc., the tiny telehealth company best known for its MangoRx men’s wellness brand, is suddenly at the center of the red‑hot obesity drugs market after unveiling a partnership with Eli Lilly and Novo Nordisk to offer official access to their blockbuster GLP‑1 weight‑loss medications Zepbound and Wegovy.GlobeNewswire+1
13 November 2025
····
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stock Market Today (Nov. 11, 2025): Dow Closes at a Record as AI Shares Stumble; FTSE 100 Hits New High on BoE Cut Bets

The Dow Jones set a new record on Nov. 11, 2025, while the Nasdaq slipped as Nvidia fell after SoftBank disclosed a $5.8B stake sale. Europe rallied on rising BoE rate‑cut bets and Vodafone’s first dividend hike in years. Here’s what moved markets and what to watch before Thursday’s CPI.
11 November 2025
········
Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly and Company opened the week with a burst of dealmaking and Wall Street momentum. The pharma giant announced a rights deal for a pediatric blindness gene therapy from MeiraGTx, unveiled a new AI‑driven discovery partnership, and captured an analyst upgrade with a higher price target—moves that had LLY trading sharply higher intraday. Reuters+2
10 November 2025
······
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market valuereuters.com. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic became global sensations, with millions seeking their dramatic weight-loss benefits. However, 2025 has seen a sharp reversal of fortune. A “slew of headwinds has shaken investor confidence” in Novo Nordisk’s once-dominant growth storystockanalysis.com. The company’s share price has plummeted nearly 50% year-to-date amid signs that demand growth is slowing and profitability is coming under pressurereuters.com.
5 November 2025
···
Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

As of Oct. 31 close, Eli Lilly was around $862–864 Stockanalysis Marketbeat. That’s up ~9–10% from early October Nasdaq. Trading volumes have been heavy, and LLY remains near its 52-week high Marketbeat. MarketBeat notes LLY’s 50-day moving average is ~$780 Marketbeat, reflecting the recent surge. Institutional ownership is high and sentiment is bullish.
2 November 2025
·
Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000?

Eli Lilly’s stock has moved sharply in recent weeks. After languishing around the mid-$700s in late September, the stock soared in early October. Between Sept. 29 and Oct. 1 it jumped over 9%, briefly touching the low $830s ts2.tech. Analysts noted this jump was fueled by a “perfect storm” of good news: better-than-expected trial results and anticipation of strong earnings. Trading volume was heavy, and by Oct. 23 shares were holding near $818 ts2.tech, about 6% higher on the year.
30 October 2025
·

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

Eli Lilly’s stock has been on a tear this year, driven by blockbuster drug sales and upbeat guidance. As of Oct. 29, 2025, LLY traded near $813.53investing.com. After hitting highs in the mid-$850s in early October, the shares have pulled back modestly. Trading volume and technical indicators suggest a consolidation phase after the recent rallyintellectia.aiintellectia.ai.
30 October 2025
···
2025’s Best-Performing Stock Market Is Up 35% – Here’s What’s Driving the Rally

2025’s Best-Performing Stock Market Is Up 35% – Here’s What’s Driving the Rally

Stock markets around the world are on fire heading into the final days of October 2025. Hong Kong’s Hang Seng Index – up about 34–35% so far this year – is the planet’s best-performing major index Advisorperspectives. After a brutal multi-year slump, Hong Kong’s market came roaring back thanks to ultra-cheap valuations and China’s post-pandemic stimulus. Investors flooded into undervalued Chinese tech and consumer stocks, driving a dramatic rebound. As a result, the Hang Seng has erased its losses from prior years and is flirting with three-year highs Dividendtitan Dividendtitan. “The market was clearly undervalued… confidence returned, money flowed in again,” one Hong Kong analyst noted of 2025’s turnaround Dividendtitan. A series of catalysts fueled the surge – from Beijing’s big economic stimulus packages to breakthroughs in Chinese AI technology and blockbuster movie releases energizing consumer sentiment Dividendtitan Dividendtitan. Even a mid-October trade scare barely dented the momentum – the Hang Seng Volatility Index spiked, but investors quickly bought the dip, betting that U.S.-China tensions would ease Reuters Reuters. As of this week, Hong Kong stocks remain on a tear, buoyed by renewed trade-deal hopes and expectations of further Chinese policy support. The Hang Seng’s resilience – up ~30%+ in
29 October 2025
···
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Sources: CPHI Frankfurt event coveragecontractpharma.comgxpnews.net; GxP Newsgxpnews.netgxpnews.net; The Medicine Maker/Conexiantconexiant.comconexiant.com; GlobeNewswireglobenewswire.com; Evaluate Pharma forecastevaluate.comevaluate.com; Reutersreuters.com; TechStock² / TS2 Techts2.techts2.tech; TS2 Techts2.techts2.tech.
28 October 2025
····

Eli Lilly (LLY) Stock Soars on Obesity-Drug Boom — Is $1,000 Next?

Eli Lilly has been on a tear in October 2025. After closing around $726 on Sept. 29, the stock surged more than 9% in the following days, briefly spiking to about $832 on Oct. 1ts2.techts2.tech. Trading volume was heavy and analysts pointed to a “perfect storm” of news – Eli Lilly’s weight-loss and Alzheimer’s drug advances were cited as key drivers. As one tech-stock analysis observed, traders noted “bullish options activity and growing excitement over Lilly’s weight-loss drugs and Alzheimer’s research” fueling the rallyts2.tech. By Oct. 23, LLY was trading near $818tradingview.com, solidly above its pre-September levels. Overall, the stock is up roughly 6% year-to-date, about matching the S&P 500 health-care indextradingview.com.
23 October 2025
··
Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks are starting today on cautiously optimistic footing. Futures were little changed this morning after a batch of earnings delivered both relief and warnings. Netflix shocked investors with a rare earnings miss, sending its stock down ~6–7% in pre-market tradingreuters.com. And chipmaker Texas Instruments sank nearly 9% after issuing a bleak sales forecast, which in turn dragged down other semiconductor namesreuters.com. Those disappointments put a slight chill on Nasdaq futures. “We’re at a bit of a point of indecision, where nobody feels particularly strongly about anything,” noted Michael Green of Simplify Asset Management, observing that even earnings surprises aren’t moving markets much in this wait-and-see environmentreuters.com.
22 October 2025
···········
1 … 10 11 12 13 14
Follow on Google News
Add as preferred source Open in Google News